Mary-Ellen Taplin, M.D., Dana-Farber Cancer Institute (IMAGE)

Dana-Farber Cancer Institute

Mary-Ellen Taplin, M.D., Dana-Farber Cancer Institute

Caption

Mary-Ellen Taplin, M.D., of Dana-Farber Cancer Institute, and colleagues have demonstrated that a hormone-depleting drug approved for the treatment of metastatic prostate cancer can help eliminate or nearly eliminate tumors in many patients with aggressive cancers that have yet to spread beyond the prostate, according to a clinical study to be presented at the annual meeting of the American Society of Clinical Oncology June 1-5 in Chicago.

Credit

Sam Ogden

Usage Restrictions

None

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.